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Abstract
Objective:  To  describe  the  antimicrobial  activity  of  -defensin-2  produced  in  the  mammary
gland and  secreted  in  human  breast  milk.
Methods:  The  peptide  production  was  performed  by  DNA  cloning.  -defensin-2  levels  were
quantiﬁed in  61  colostrum  samples  and  39  mature  milk  samples  from  healthy  donors,  by  an
indirect  enzyme-linked  immunosorbent  assay  (ELISA).  Using  halo  inhibition  assay,  this  study
assessed  activity  against  seven  clinical  isolates  from  diarrheal  feces  of  children  between  0  and
2  years  of  age.  The  activity  of  -defensin-2  against  three  opportunistic  pathogens  that  can
cause  nosocomial  infections  was  determined  by  microdilution  test.
Results: The  peptide  levels  were  higher  in  colostrum  (n  =  61)  than  in  mature  milk  samples
(n =  39),  as  follows:  median  and  range,  8.52  (2.6-16.3)  g/ml  versus  0.97  (0.22-3.78),  p  <  0.0001;
Mann-Whitney  test.  The  recombinant  peptide  obtained  showed  high  antimicrobial  activity
against  a  broad  range  of  pathogenic  bacteria.  Its  antibacterial  activity  was  demonstrated
in a  disk  containing  between  1--4  g,  which  produced  inhibition  zones  ranging  from  18  to
30  mm  against  three  isolates  of  Salmonella  spp.  and  four  of  E.  coli.  -defensin-2  showed  min-
imum  inhibitory  concentrations  (MICs)  of  0.25  g/mL  and  0.5  g/mL  for  S.  marcescen  and  P.
aeruginosa,  respectively,  while  a  higher  MIC  (4  g/mL)  was  obtained  against  an  isolated  of
multidrug-resistant  strain  of  A.  baumannii.
 Please cite this article as: Baricelli J, Rocafull MA, Vázquez D, Bastidas B, Báez-Ramirez E, Thomas LE. -defensin-2 in breast milk
isplays a broad antimicrobial activity against pathogenic bacteria. J Pediatr (Rio J). 2015;91:36--43.
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Conclusions:  To  the  authors’  knowledge,  this  study  is  the  ﬁrst  to  report  -defensin-2  levels  in
Latin American  women.  The  production  and  the  activity  of  -defensin-2  in  breast  milk  prove
its  importance  as  a  defense  molecule  for  intestinal  health  in  pediatric  patients.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.    
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-defensina  2  no  leite  materno  mostra  uma  ampla  atividade  antimicrobiana  contra
bactérias  patogênicas
Resumo
Objetivo:  Descrever  a  atividade  antimicrobiana  da  defensina-beta  2  na  glândula  mamária  e
secretada  no  leite  materno  humano.
Métodos:  A  produc¸ão  de  peptídeos  foi  realizada  por  clonagem  de  DNA.  Os  níveis  de  defensina-
beta 2  foram  quantiﬁcados  em  61  amostras  de  colostro  e  39  de  leite  maduro  de  doadoras
saudáveis pelo  teste  ELISA  indireto.  Por  um  ensaio  de  halo  de  inibic¸ão,  avaliamos  a  atividade
contra  sete  isolados  clínicos  diarreicos  de  crianc¸as  entre  0  e  2  anos.  A  atividade  da  defensina
2  contra  três  patógenos  oportunistas  que  podem  causar  infecc¸ões  nosocomiais  foi  determinada
pelo  teste  de  microdiluic¸ão.
Resultados: Os  níveis  de  peptídeos  estavam  signiﬁcativamente  maiores  nas  amostras  de  colostro
(n =  61)  que  de  leite  maduro  (n  =  39),  como  segue:  8,52  (2,6-16,3  g/mL)  mediana  e  faixa  em
comparac¸ão  a  0,97  (0,22-3,78),  p  <  0,0001;  teste  de  Mann-Whitney.  O  peptídeo  recombinante
foi obtido  da  alta  atividade  antimicrobiana  demonstrada  contra  uma  ampla  gama  de  bactérias
patogênicas.  Sua  atividade  antibacteriana  foi  demonstrada  em  um  disco  contendo  entre  1-
4  g,  que  produziu  zonas  de  inibic¸ão  entre  18  e  30  mm  contra  três  isolados  de  Salmonella  spp.
e  quatro  de  E.  coli.  A  defensina-beta  2  demonstrou  concentrac¸ões  inibitórias  mínimas  (CIMs)
de  0,25  g/mL  e  0,5  g/mL  para  S.  marcescen  and  P.  aeruginosa,  ao  passo  que  uma  CIM  maior
(4  g/mL)  foi  obtida  contra  um  isolado  de  cepa  multirresistente  de  A.  baumannii.
Conclusões:  Até  onde  sabemos,  este  estudo  é  o  primeiro  a  relatar  níveis  de  defensina  em  mul-
heres da  América  Latina.  A  produc¸ão  e  a  atividade  da  defensina  2  no  leite  materno  comprovam
sua importância  como  uma  molécula  de  defesa  para  a  saúde  intestinal  em  pacientes  pediátricos.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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The  World  Health  Organization  reports  that  6.6  million  chil-
dren under  the  age  of  5  died  in  2012.  Moreover,  44%  of
those deaths  occurred  during  the  neonatal  period.  From
the end  of  the  neonatal  period  through  the  ﬁrst  5  years  of
life, the  main  causes  of  death  are  pneumonia,  diarrhea,  and
malaria. Malnutrition  is  the  underlying  contributing  factor
in approximately  45%  of  all  child  deaths,  making  children
more vulnerable  to  severe  diseases.1 Over  half  of  these  early
child deaths  are  due  to  conditions  that  could  be  prevented
or treated  with  access  to  simple,  affordable  interventions;
one of  them  is  breastfeeding.
Solely during  lactancy,  humans  confront  the  challenge  of
survival by  means  of  breast  milk.  Human  milk  is  associated
with protection  against  diarrheal  diseases,  respiratory-tract
infections, and  necrotizing  enterocolitis  (NEC).2--5 Protec-
tion against  infection  in  breastfed  infants  appears  to  occur
through a  variety  of  complementary  acquired  and  innate
defense factors  found  in  human  milk,  including  oligosaccha-
rides and  their  glycoconjugates,6 and  antimicrobial  peptides
(AMPs).7,8
Among  AMPs,  the  defensins  family  constitutes  an  impor-
tant part  of  the  innate  immune  response  in  ﬂuids  secretion.
b
o
rncreasing  evidence  suggests  the  importance  of  defensins
n the  immune  response.  Results  in  recent  studies  on
he homeostatic  and  disease-ﬁghting  activities  of  human
efensins point  to  their  key  relevance  in  several  pediatric
isorders. For  example,  high  -defensin-2  (hBD2)  concen-
rations reﬂecting  strong  intestinal  immune  responses  were
ssociated  with  moderate  courses  of  NEC.9 However,  infants
ith severe  NEC  showed  no  increase  in  fecal  hBD2  con-
entrations before  and  during  the  disease.  These  studies
uggest that  a speciﬁc  deﬁciency  of  innate  defense  acti-
ation in  extremely-low  birth  weight  (ELBW)  infants  rather
han an  impaired  intestinal  epithelial  barrier  leads  to  a
ore severe  course  of  NEC.9 In  this  context,  the  intake  of
BD2 from  breast  milk  gains  importance.  Notably,  intestinal
BD2 levels  correspond  to  both  defensin  in  breast  milk7,8,10
nd  secretions  of  intestinal  epithelial  cells.  The  latter  are
nduced by  catalytic  antibodies  contained  in  breast  milk,
cting through  protease-activated  receptor-2  present  in  the
lasma membrane.11
The  concentrations  of  total  and  speciﬁc  components
f human  breast  milk  vary  between  mothers,  diurnally,
ased on  infant’s  gestational  age,  and  over  the  course
f lactation.10,12 Presence  of  intact  hBD2  has  also  been
eported in  infant  feces,  which  shows  that  hBD2  tends  to
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ithstand  the  digestive  processes  of  the  gastrointestinal
ract.13 Indeed,  it  has  been  proposed  that  defensin  quantiﬁ-
ation in  feces  could  be  an  effective  biomarker  of  intestinal
ealth and  disease  in  pediatric  population.14 The  resistance
f hBD2  to  digestion  would  increase  its  availability,  which
ould allow  to  protect  the  entire  mucosal  surface  of  the
astrointestinal tract.
This  study  had  a  two-fold  aim.  First,  to  quantify  the
BD2 in  breast  milk  from  Venezuelan  donors.  Second,
o characterize  the  antimicrobial  activity  of  BD2  against
oth bacterium  associated  with  enterocolitis  in  infants  and
gainst Gram-negative  bacteria  associated  with  nosocomial
nfections.
aterials and methods
aterials
he  TOPO® TA  Cloning® kit  for  sequencing  and  the  pET
irectional TOPO® expression  kit  were  purchased  from  Invi-
rogen (Invitrogen  Corp.,  Carlsbad,  Califórnia,  USA).  All
ther reagents  were  of  analytical  reagent  grade.
uman  milk  collection  and  preparation
n  informed  consent  from  all  donors  involved  in  this  study
as obtained  prior  to  obtaining  and  processing  the  samples.
one of  the  donors  in  the  study  had  history  of  rheumatologic,
espiratory, cardiovascular,  or  gastrointestinal  diseases.  The
nclusion criteria  were  healthy  lactating  mothers  with  term
elivery. The  exclusion  criteria  were  mothers  who  had  had
esarean deliveries,  were  receiving  antibiotic  treatment  on
uspicion of  infection,  or  with  a  history  of  autoimmune
iseases. Samples  from  day  one  to  day  seven  after  child-
irth were  denoted  as  colostrum,  whereas  samples  collected
eyond the  tenth  day  of  birth  were  termed  mature  milk.
This  study  obtained  61  colostrum  and  39  mature  samples.
ll samples  were  collected  using  a  standardized  protocol
pproved by  the  Bioethics  Committee  of  the  Clinical  Uni-
ersity Hospital  at  Universidad  Central  de  Venezuela  (UCV).
amples were  collected  from  healthy  human  mothers  (18  to
0 years  old)  with  support  from  the  milk  bank  service  of  the
linical University  Hospital.  Prior  to  extraction,  the  nipples
ere cleaned  and  swabbed  with  warm  sterile  water.
Samples  were  collected  from  one  breast,  and  centrifuged
t 4 ◦C  (1,000  ×  g  for  15  min)  so  that  samples  had  a  pellet  of
ells at  the  bottom  and  a  fat  layer  at  the  top.  Whey  super-
atant in  the  middle  was  aliquoted  and  frozen  at  −80 ◦C.
hen ready  for  use,  milk  was  thawed  at  4 ◦C.
ells  cultures
ultured  SKBR3  cells  (human  breast  adenocarcinoma  cell
ine, HTB-30  cat.,  No.  11965-092  American  Type  Culture  Col-
ection (ATCC),  Manassas,  USA).acterial  strains
linical  isolates:  Acinetobacter  baumannii  (multidrug-
esistant strain  isolated  from  a  patient  suffering  nosocomial
A
d
w
wBaricelli  J  et  al.
nfection  of  Caracas  University  Hospital-UCV)  was  kindly  pro-
ided by  Dr.  G.  Alonso  (Instituto  de  Biología  Experimental-
CV). In  total,  seven  enteropathogens  from  children’s
iarrheal samples  were  tested,  three  belonging  to  genus
almonella (Salmonella  paratyphi,  Salmonella  arizona,
almonella sp.)  and  four  different  isolates  of  E.  coli.  All
ere identiﬁed  with  standard  bacteriological  assays  using
 Vitek® 32  and  GNI  card  (BioMérieux  Inc.,  Missouri,  USA).
The Pseudomonas  aeruginosa  ATCC  276532  strain  was
ourtesy of  Dr.  Takiff  of  Molecular  Genetics  Laboratory-  IVIC.
scherichia coli  ATCC  25922  was  obtained  from  ATCC.
nimals
ive-month-old  brown  hens  were  bought  from  a  local  farmer.
everse  transcription  polymerase  chain  reaction
RT-PCR)
KBR3  cells  were  grown  to  80%  conﬂuence.  Cells  were  then
reated for  4  h  with  lipopolysaccharide  (LPS)  (1  g/mL),  as
escribed previously.11 RNA  was  extracted  from  SKBR3  cells
sing Trizol® (Invitrogen,  Carlsbad,  CA,  USA)  according  to
he manufacturer’s  instructions.  BD2  cDNA  was  ampliﬁed
y RT-PCR  using  sense  and  antisense  hBD2  primers,  as  pre-
iously reported.11 Directional  cloning  of  PCR  product  was
chieved using  designed  primers  with  particular  restriction
ites.
hBD2S:CCCGGGCATGAGGGTCTTGTATCTCCTCTTC
hBD2R:GAATTCGGAGCCCTTTCTGAATCCGCA; (255  bp)
The resulting  PCR  products  were  puriﬁed  and  encoding
ull-length gene  hBD2  from  SKBR3  cells  was  cloned  in  pET
00 vector  (Champion  pET  directional  TOPO  expression  and
loning kit,  Invitrogen).  The  fusion  proteins  were  expressed
n an  E.  coli  (Strain  BL21  DE3)  system  according  to  manu-
acturer’s instructions.  The  recombinant  fusion-protein  was
sed in  both  antimicrobial  activity  assays.  It  also  was  used
o produce  antibodies  from  hens’  egg  yolks.
roduction  and  puriﬁcation  of  antibodies  from  egg
olks for  recombinant  hBD2
he  antigen  100  g  (recombinant  hBD2)  was  diluted  in  PBS
pH 7.2)  and  emulsiﬁed  with  an  equal  volume  of  incomplete
reund’s adjuvant.  Suspension  was  injected  subcutaneous
n the  birds.  Further  injections  of  the  protein,  were  given
o the  hens  7,  21,  31,  and  42  days  later.  IgY  was  puriﬁed
rom individual  eggs  using  a  commercial  Chicken  IgY  Puriﬁ-
ation kit  (Pierce  Biotechnology,  Cat  N◦ 44918,  Illinois,  USA)
ollowing manufacturer  instructions.  Prior  to  the  immuniza-
ion, IgY  was  puriﬁed  in  order  to  obtain  pre-immune  IgY  to  be
sed as  negative  control  in  the  enzyme-linked  immunosor-
ent assay  (ELISA)  standardization.
BD2  quantiﬁcation  by indirect  ELISAn  indirect  ELISA  was  designed  for  quantiﬁcation  of  -
efensin 2.  The  96-well  immunoplates  (MaxisorpTM;  Nunc)
ere coated  overnight  with  clariﬁed  milk  samples  and
ith the  -defensin  1  or  2  peptides,  used  as  standards.
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ples (0.97  [0.22-3.78];  p  <  0.0001;  Mann-Whitney  test).  The
hBD2 quantiﬁcation  in  human  milk  samples  showed  inter-
individual variability  as  well  as  in  each  stage  of  lactation
(Fig. 1).
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Figure  1  Defensin  levels  found  in  the  breast  milk  samples
from the  100  donors.  The  horizontal  lines  indicate  the  median
of defensin  concentration  in  colostrum  and  mature  samples.  TheMilk  -defensin-2  is  active  against  pathogens  
Commercial  recombinant  Human  BD-1  and  BD-2  (Cat  N◦
300-51  A  and  300-49;  Peprotech  México)  were  used.  Stan-
dards and  samples  were  diluted  into  carbonate  coating
buffer, and  plates  were  blocked  during  4  h  in  200  mL  blocking
buffer. Polyclonal  IgY  chicken  anti-human  -defensin-2  was
diluted in  blocking  buffer  1:1000  and  added  (100  L).  Two
hours later,  secondary  rabbit  anti-immunoglobulin  Y  (IgY)
peroxidase-conjugate (1:5000  dilution)  in  blocking  buffer
was added  (100  L)  and  incubated  for  1.5  h.  The  colorimetric
reaction was  performed  as  described  previously.11 As  a  con-
trol, samples  in  each  plate  were  run  with  pre-immune  IgY
or without  primary  antibodies  to  ascertain  any  unspeciﬁc
binding. The  defensin  concentration  of  samples  was  com-
puted by  interpolating  three  standard  curves  constructed  via
serial  twofold  dilutions  of  the  recombinant  hBD2.  The  opti-
mal sample  dilution  was  established  by  titration  and  varied
between donors.  The  control  tests  demonstrated  that  the
polyclonal used  for  -defensins-2  were  selective.  Thus,  the
IgY anti  -defensin  2  did  not  react  with  -defensin  1.
Antimicrobial  activity  assays
The  assayed  strains  were  grown  in  liquid  Luria-Bertani  (LB)
medium to  OD600 ∼1.0.  The  resulting  suspensions  were
diluted to  a  concentration  of  ∼104 CFU  per  mL.  A  100  L
aliquot of  LB  was  dispensed  into  96-well  plates.15 The
antibacterial activity  of  hBD2  was  evaluated  with  seri-
ally diluted  peptide  to  obtain  concentrations  of  8;  4;  2;
1; 0.5;  0.25  and  0.125  g/mL.  A  growth  control  contain-
ing no  hBD2  and  a  sterility  control  without  inoculum  were
also included  for  each  strain.  Plates  were  incubated  at
35 ◦C  and  measurements  of  turbidity  at  600  nm  using  the
Synergy HT  multidetection  microplate  reader  (Synergy  HT,
Bio-Tek Instruments,  Vermont,  USA).  In  a  single  experiment,
each hBD2  concentration  was  tested  in  triplicate.  Each
microorganism was  analyzed  in  at  least  three  independent
experiments. Statistical  analysis  and  dose  response  curves
were obtained  using  the  K4  software  provided  by  Synergy
HT (Bio-Tek  Instruments,  Vermont,  USA).  Minimum  inhibitory
concentrations (MICs)  were  determined  from  the  growth
inhibition proﬁles  curves,  measured  with  an  absorbance  of
OD6 00  nm,  and  represent  the  lowest  concentration  of  the
hBD2 that  inhibited  the  bacterial  growth  by  90%  at  24  h  of
culture.
Antimicrobial  susceptibility  by  disk  diffusion  tests
In  vitro  susceptibility  of  clinical  isolates  to  defensin  could
be roughly  determined  by  disk  diffusion  tests.16 Kanamycin
was used  as  an  internal  control.  Disks  were  prepared  using
a stock  solution  of  antibiotic  adding  antimicrobial  solution
to each  paper  disk,  using  Filter  paper  sheets  from  BioRad
(Thick blot  paper  catalog  No.  170-3956).  They  were  pre-
pared within  one  hour  prior  to  the  application  to  the  plates,
allowing approximately  30  minutes  for  antibiotic  absorption.
Prepared disks  were  not  stored  and  were  dry  before  appli-
cation.After 24  h  of  incubation,  the  inhibition  zones  were  mea-
sured. Diameter  of  the  areas  of  inhibition  was  converted
to the  categories  of  susceptible,  intermediate,  or  resistant
(S, I,  or  R,  respectively)  according  to  standard  tables.  The
p
1
0
s39
nterpretation,  breakpoints,  and  categorization  scheme  fol-
owed  the  Clinical  and  Laboratory  Standard  Institute  (CLSI)
ecommendations.17
tatistical  analysis
raphical  presentation  and  statistical  analysis  of  the  data
ere performed  using  GraphPad  Prism  (version  4.0)  software
GraphPad Software  Inc.,  California,  USA).  The  Mann-
hitney U  test  was  used  for  comparison  between  groups.
tatistical signiﬁcance  was  set  to  p  <  0.05.
esults
xpression  of  the  recombinant  hBD2  peptide
he  recombinant  hBD2  peptide  was  produced  from  mam-
ary epithelial  cell  cDNA  based  on  the  known  nucleotide
equence of  hBD2  (also  known  as  DEFB4A).  Its  identity  was
et by  DNA  sequence  analysis.  This  recombinant  peptide  was
sed to  produce  polyclonal  IgY,  whose  antibodies  were  used
n indirect  ELISA  for  detection  and  quantiﬁcation  of  human
-defensin in  human  milk  samples.
uantiﬁcation  of  hBD2  in  human  breast  milk
amples
 total  of  100  healthy  Venezuelan  mothers  were  included
n this  study.  The  peptide  levels  were  signiﬁcantly  higher  in
olostrum (8.52  [2.6-16.3  g/mL])  than  in  mature  milk  sam-eptide levels  were  signiﬁcantly  higher  in  colostrum:  8.52  (2.6-
6.3 g/mL)  median  and  range,  than  in  mature  milk  samples
.97 (0.22-3.78).  A  Mann-Whitney  U  test  was  used  for  compari-
on between  groups,  P  <  0.0001.
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ntimicrobial  activity  assays
he  recombinant  peptide  was  analyzed  for  anti-
nteropathogens  activity.  Results  of  these  experiments
re shown  in  Table  1  and  Fig.  2.
According  to  the  CLSI,  control  of  Kanamycin  at  a  concen-
ration of  30  g  in  the  disk  must  produce  an  inhibition  halo
f 18-25  mm  against  E.coli  ATCC  25922.17 In  the  present
tudy, the  control  showed  an  inhibition  of  20  mm  (Table  1).
here is  no  standard  diameter  measure  for  inhibition  by
efensin. However,  strong  bactericidal  properties  were
bserved against  all  seven  isolates  obtained  from  diarrheal
tool with  diameters  over  18  mm.
Additionally, hBD2  exhibited  antimicrobial  activity
gainst three  strains  representative  of  bacterial  species
nvolved in  nosocomial  infections.  MICs  of  0.25  g/mL  and
.5 g/mL  were  observed  for  S.  marcescen  and  P.  aerugin-
sa, while  a  relatively  higher  MIC  (4  g/mL)  was  observed
i
d
e
e
Table  1  Minimum  inhibitory  concentrations  of  human  beta  defens
and  E.coli.
Antimicrobial  agent  Disk
content
g
Bacteria
strain
Kanamycin  30  Escherichia  coli  ATCC  
CONTROL ASSAY
hBD2  1  Escherichia  coli  spp.  I
hBD2 4  
hBD2  8  
Kanamycin  30  
hBD2  1  Escherichia  coli  spp.  I
hBD2  4  
hBD2  8  
Kanamycin  30  
hBD2  1  Escherichia  coli  spp.  I
hBD2  4  
hBD2  8  
Kanamycin  30  
hBD2  1  Escherichia  coli  spp.IS
hBD2  4  
hBD2  8  
Kanamycin  30  
hBD2  1  Salmonella  paratyphi
ISOLATE 5
hBD2  4  
hBD2  8  
Kanamycin  30  
hBD2  1  Salmonella  spp.
ISOLATE 6
hBD2  4  
hBD2  8  
Kanamycin  30  
hBD2  1  Salmonella  arizona
ISOLATE 7
hBD2  4  
hBD2  8  
Kanamycin  30  Baricelli  J  et  al.
gainst  a  clinical  isolate  of  a  multidrug-resistant  strain  of  A.
aumannii.
iscussion
evelopmental  delays  in  the  immune  system  of  human
nfants are  compensated  by  the  mammary  gland,  pro-
iding the  necessary  protection.  Lactancy  provides  not
nly nourishment  but  also  vital  protection  against  envi-
onmental pathogens.  Even  with  high  interindividual
ariability in  levels  of  different  milk-related  protecting  fac-
ors, breastfeeding  provides  protection  against  necrotizing
nterocolitis,4 gastrointestinal  infection,3 and  respiratory
nfections2 in  the  newborn.  This  article  addressed  the  pro-
uction of  hBD2  in  Venezuelan  breast  milk  donors  and
xplored the  potential  protective  effect  of  hBD2  against
nteropathogens isolates  from  children’s  diarrheal  stool.
in-2  peptide  against  seven  clinical  isolate  strains  of  Salmonella
Diameter  of  inhibition  zone  in  mm
Resistant  Intermediate  Susceptible
25922 13  14-17  18
0 ±  0.5
SOLATE  1  10  ±  0.5
16  ±  0.4
19  ±  0.4
22  ±  0.3
SOLATE  2  20  ±  0.3
23  ±  0.4
27  ±  0.5
29  ±  0.6
SOLATE  3  22  ±  0.3
24  ±  0.5
26  ±  0.3
27  ±  0.3
OLATE  4  15  ±  0.3
18  ±  0.5
22  ±  0.4
30  ±  0.6
22  ±  0.3
25  ±  0.3
29  ±  0.6
16  ±  0.3
17 ±  0.5
22  ±  0.5
26  ±  0.4
28  ±  0.3
18  ±  0.3
19  ±  0.3
21  ±  0.4
33  ±  0.4
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Figure  2  Effect  of  human  beta  defensin-2  on  bacterial  growth.  Optical  density  at  different  times  of  growth  in  Luria-Bertani
medium was  followed  for  three  strains,  (A)  S.marcesens,  (B)  P.  aeruginosa,  and  (C)  A.  baumannii,  during  treatment  with  serial
dilutions  of  the  recombinant  peptide.  The  higher  peptide  concentration  tested  was  at  8  g/mL.  The  test  was  performed  three
times  on  different  days,  and  the  means  and  standard  deviations  are  indicated.  A  statistically  signiﬁcant  difference  was  observed
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i(p  ≥  0.05).  The  minimum  inhibitory  concentrations  (MIC)  of  d
required to  inhibit  growth  >  90%  of  the  control.  MIC  values  are  
to  human  beta  defensin-2.
Wang  et  al.  reported  that  hBD2  levels  in  Chinese  Han
mothers differed  between  colostrum  and  mature  milk.18
In  the  colostrum,  the  concentration  ranges  of  hBD2  were
0.31-19.12 ng/mL,  compared  to  52.65-182.29  pg/mL  found
in mature  milk.  In  agreement  with  Wang  et  al.,  the  present
study also  observed  higher  hBD2  levels  in  colostrum  than
in mature  milk;  however,  both  groups  presented  higher  lev-
els  of  hBD2  than  the  Chinese  Han  group.18 The  differences
between the  hBD2  expression  levels  between  both  studies
are striking,  considering  that  both  assessed  an  equal  number
of donors.  Therefore,  these  differences  could  be  attributed
to the  ethnicity  of  the  groups  involved.  A  recent  article
by Burch  et  al.  highlighted  that  race/ethnicity  appears  to
have an  inﬂuence  on  the  level  of  immune  factors  in  breast
milk;19 the  present  results  appear  to  support  these  ﬁndings.
To the  best  of  the  authors’  knowledge,  this  study  is  the  ﬁrst
report of  the  characterization  of  defensin  levels  in  human
milk in  Latin  American  women,  and  the  present  ﬁndings  help
to reinforce  the  recommendation  of  exclusive  breastfeeding
aiming to  protect  the  health  of  at-risk  children.  Defensins
have been  found  at  a  concentration  of  1--10  mg/mL  in  neu-
trophil granules20,21 and  at  concentration  of  20--100  mg/mL
in porcine  tongue  epithelium.22 It  is  believed  that  lower
concentrations (0.1--1  mg/ml)  of  -defensins  might  induce
chemotaxis;23,24 the  present  results  showcase  a  similar  range
of concentration.
In agreement  with  the  present  results,  Castellote  et  al.25
reported  that  the  concentration  of  immune  factors  in
colostrum samples  is  richer  than  both  transitional  and
mature milk.  They  suggested  that  the  high  content  of  active
factors in  premature  infants  and  their  inverse  correlations  to
birth weight  could  indicate  that  their  concentration  in  milk
r
t
p
sin  for  each  strain  is  considered  as  the  lowest  concentration
ated  in  square  brackets,  as  determined  after  24  h  of  exposure
s  modulated  by  the  neonate’s  requirements.  The  mecha-
isms responsible  for  differences  in  the  composition  of  milk
etween stages  of  lactation  have  yet  to  be  established.
In  vitro  bactericidal  activity  of  human-defensin-2
gainst  enteropathogens  and  nosocomial  strains  has  been
eported.26 Indeed,  each  of  the  beta-defensins  character-
zed to  date  has  the  ability  to  kill  or  inhibit  in  vitro  a  variety
f bacteria.  This  activity  varies  particularly  with  concentra-
ions of  salt  and  plasma  proteins  in  the  assay.21 Thus,  direct
omparison of  the  MIC  could  be  non-determinant.  However,
t is  striking  that  the  concentration  at  which  this  defensin
hows antimicrobial  activity  is  the  same  as  human  milk’s,
ighlighting its  physiological  function.
The  role  of  this  peptide  in  the  intestinal  physiology  of
he newborn  has  been  assumed  as  antimicrobial.  Bacterial
iarrhea is  one  of  the  main  causes  of  infection  in  childhood.
herefore, it  is  important  to  determine  the  activity  of  hBD2
n isolates  of  diarrheic  clinical  cases.  In  the  present  study,
our different  isolates  of  E.coli  and  three  of  Salmonella
pp. were  used.  In  all  cases,  an  inhibitory  growth  activity
as observed  when  comparing  with  the  reference  parame-
ers of  the  antibiotic  kanamycin  (with  isolate  referral  strain
.coli ATCC  25922).  Kapel  et  al.13 described  elevated  fecal
evels of  hBD2  in  pediatric  patients  with  both  ulcerative
olitis (UC)  and  Crohn’s  disease  (CD)  compared  to  healthy
ontrols. They  found  a  three-to-four  fold  increase  in  fecal
BD2 levels  in  children  with  CD  as  opposed  to  a  >  ten-fold
ncrease in  fecal  hBD2  levels  for  UC.  Notably,  Barrera  et  al.11eported  that  intestinal  epithelial  cells  increased  the  secre-
ion of  hBD2  after  treatment  with  catalytic  antibodies  with
rotease activity  puriﬁed  from  breast  milk.  Therefore,  it
hould be  considered  that  the  content  of  hBD2  in  stool
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amples  corresponds  to  the  sum  of  the  intestinal  peptide
roduction plus  the  direct  intake  through  breast  milk.  More-
ver, Hiratsuka  et  al.27 have  indicated  a  reduced  activity
f beta-defensins  in  cystic  ﬁbrosis,  suggesting  that  beta-
efensins may  play  an  important  role  in  the  pathological
rocess of  chronic  respiratory  tract  infection.  Besides  its
ntimicrobial activity,  other  activities  for  hBD2  have  been
eported. Findings  of  Gambichler  et  al.28 showed  altered
xpression patterns  of  hBD2  in  non-ulcerated  basal  cell  car-
inoma, suggesting  that  hBD2  may  also  play  a  role  in  the
athogenesis of  this  non-melanoma  skin  cancer.  Recently,  Li
t al.29 indicated  that  gene  therapy  with  hBD2  could  mediate
peciﬁc antitumor  immunity  and  increase  local  antitumor
ffects. Additionally,  hBD2  has  shown  chemotactic  activ-
ty for  monocytes,  macrophages,  neutrophils,  and  immature
endric cells.15
Finally,  the  antimicrobial  activity  of  recombinant  hBD2
as determined  over  three  Gram-negative  bacteria  (S.
arcescen, P.  aeruginosa,  A.  baumannii)  that  can  be  oppor-
unistic pathogens  in  humans,  affecting  individuals  with
ompromised immune  systems.  A  major  factor  in  their
rominence as  pathogens  is  their  intrinsic  resistance  to
ntibiotics and  disinfectants,  which  makes  them  important
ubjects in  the  ﬁeld  of  nosocomial  infection.  Recombi-
ant hBD2  showed  inhibited  growth  in  all  tested  bacteria.
he hBD2  susceptibility  showed  by  multidrug-resistant  A.
aumannii strains  is  in  agreement  with  that  reported  by
outsias et  al.,26 who  suggested  that,  besides  mutations  that
onfer resistance  to  certain  antibiotics,  this  bacteria  suf-
ers mutations  that  affect  energy  generation  required  for
aintenance of  its  membrane  integrity  or  affect  membrane
tructure itself,  leading  to  hyper-susceptibility  to  hBD2.
he lytic  action  of  AMPs  occurs  through  a  binding  event
hereby the  positively  charged  peptides  interact  with  the
nionic plasma  membranes  of  targeted  microorganisms.  It
as been  known  that  the  antimicrobial  activity  of  hBD2  and
ther AMPs  is  highly  sensitive  to  the  presence  of  divalent
ations, serum,  and  anionic  macromolecules  such  as  gly-
osaminoglycans. However,  many  of  these  AMPs  are  still  able
o confer  protection  under  these  conditions.  In  this  regard,
ther immunomodulatory  properties,  such  as  cell  migration,
urvival, proliferation,  and  induction  of  immune  mediators,
ould probably  be  more  signiﬁcant  in  their  disease-ﬁghting
echanisms.30
The  misuse  of  antibiotics  has  led  to  horizontal  gene
ransfer among  microbes  and  stimulated  their  evolutionary
otential to  develop  resistance  against  conventional  antimi-
robials. In  consequence,  bacterial  resistance  to  antibiotics
s an  escalating  problem  in  modern  medicinal  treatment
f infectious  diseases,  as  shown  by  a  growing  number
f immunocompromised  patients  with  nosocomial  infec-
ions. New  therapeutic  approaches  are  needed  in  order  to
emporarily overcome  the  resistance  problem.  Since  antimi-
robial peptides  are  products  of  long-term  evolution  in
ature, the  study  of  this  peptide  family  could  provide  a
easible solution.
In summary,  the  female  population  in  this  study  had  hBD2
ecreted in  milk,  suggesting  that  race/ethnicity  could  inﬂu-
nce  the  level  of  immune  factors  in  breast  milk.  High  levels
f peptide  found  in  colostrum  suggest  the  importance  of
his innate  immunity  factor  during  the  ﬁrst  days  of  life.  The
BD2 peptide  showed  antimicrobial  activity  against  a  range
1Baricelli  J  et  al.
f  bacteria,  including  common  pathogens  that  cause  diar-
hea in  infants  and  gram-negative  relevant  in  nosocomial
nfections. The  activity  and  high  hBD2  content  in  breast  milk
ighlight the  superiority  of  breastfeeding  in  the  nutrition  of
uman infants.
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